Edwards announces one-year data on transfemoral transcatheter tricuspid valve replacement

London , nov. 27, 2022 /prnewswire/ -- edwards lifesciences corporation (nyse: ew) announced that one-year results on patients treated in the single-arm, prospective, global, multi-center triscend study of the company's evoque transcatheter tricuspid valve replacement system demonstrated favorable safety, efficacy and quality-of-life outcomes. the data were presented during the late-breaking trials session at pcr london valves 2022.
EW Ratings Summary
EW Quant Ranking